Welcome to our dedicated page for Bluejay Diagnostics SEC filings (Ticker: BJDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Bluejay Diagnostics, Inc. (BJDX) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, providing insight into its development of the Symphony near-patient testing platform and Symphony IL-6 Test for sepsis triage and monitoring. As an emerging growth company listed on The Nasdaq Capital Market, Bluejay files periodic and current reports that describe its clinical, manufacturing, financing, and governance activities.
Through Forms 10-K and 10-Q, investors can review Bluejay’s descriptions of the Symphony System, its regulatory plans for a 510(k) submission for the Symphony IL-6 test, and discussions of risks, liquidity, and capital requirements. Current reports on Form 8-K detail material events such as amendments to the Master Service Agreement and Master Supply Agreement with SanyoSeiko Co., Ltd., changes to license and supply arrangements with Toray Industries, Inc., private placements of common stock, pre-funded warrants and Series F warrants, and the implementation of a 1-for-50 reverse stock split.
This page also provides access to exhibits referenced in Bluejay’s 8-K filings, including forms of warrants, securities purchase agreements, registration rights agreements, and amendments to key manufacturing and licensing contracts. These documents help explain how Bluejay is structuring its manufacturing partnerships, securing access to cartridge components, and arranging financing to support clinical trials and regulatory activities for the Symphony IL-6 test.
Stock Titan enhances these filings with AI-powered summaries that highlight the main points of lengthy documents, such as how a particular financing affects share structure or how a contract amendment changes manufacturing responsibilities. Users can quickly identify disclosures related to capital raises, reverse stock splits, material agreements, and other events without reading every page of the underlying filing. Real-time updates from EDGAR ensure that new Bluejay filings, including any future proxy statements or insider transaction reports, are added as they become available, giving investors a structured view of BJDX’s regulatory history and ongoing obligations.
Bluejay Diagnostics, Inc. is soliciting proxies for its 2026 Annual Meeting of Stockholders and asks holders to consider five proposals, including reelecting five directors, approving a reverse stock split (range: 1-for-2 to 1-for-20) via an amendment to the charter, increasing the 2021 Stock Plan share reserve, and ratifying Wolf & Company, P.C. as auditor. The record date for voting is April 28, 2026, and the proxy materials and the 2025 Annual Report on Form 10-K are available at the posted link. The board recommends voting FOR each proposal; the Board retains discretion to select the final reverse-split ratio (subject to a minimum public float constraint) and may abandon the split even if approved.
Bluejay Diagnostics, Inc. provides an update on patient enrollment in its pivotal SYMON-II clinical trial of the Symphony IL-6 test for sepsis triage and monitoring. The company has successfully enrolled 624 patients toward a target of 750 and expects to complete enrollment in the next 2 to 3 months, depending on site activity and patient flow.
The trial is designed to clinically validate Bluejay’s Symphony IL-6 test, which aims to deliver rapid, near-patient results in critical care settings to help clinicians assess patient severity and guide timely treatment decisions. SYMON-II is part of a broader SYMON clinical program that the company plans to use to support a 510(k) submission to the FDA for its investigational Symphony System.
Bluejay Diagnostics, Inc. entered into a securities purchase agreement with its senior leaders and directors for a small insider-funded capital raise. The company issued 62,500 shares of common stock in a private placement at $2.00 per share, generating gross proceeds of $125,000.
The purchasers were President and CEO Neil Dey, Board Chair Donald Chase, and directors Svetlana Dey, Douglas Wurth and Fred Zeidman, each acquiring 12,500 shares for their own account. The shares were sold as an unregistered offering under Section 4(a)(2) and Rule 506 of Regulation D to accredited investors, with no registration rights granted and no general solicitation used.
Bluejay Diagnostics, Inc. outlined its response to investor NorthStrive Fund II LP, which suggested that Bluejay explore acquiring a Phase‑1‑ready therapeutic program targeting refractory chronic cough to expand its pipeline.
Bluejay emphasized that its current priority is advancing its Symphony™ near‑patient critical care diagnostics platform, including completing the SYMON™ II clinical study, scaling up manufacturing, and preparing an FDA submission. The board and management, with external clinical and regulatory advisors, plan to carefully evaluate the proposed acquisition for strategic fit, potential synergies with Symphony™, and impact on existing shareholders, while remaining focused on prudent use of cash and fiduciary obligations.
Bluejay Diagnostics, Inc. filed a current report describing new clinical visibility for its Symphony IL-6 Test. An abstract based on the multicenter SYMON-I pilot study was accepted for presentation at the 2026 Society of Academic Emergency Medicine Annual Meeting in Atlanta.
The presentation will cover how interleukin-6 levels measured in the emergency department relate to organ dysfunction, assessed by Sequential Organ Failure Assessment scores over the first three days of hospitalization in sepsis patients. Bluejay also highlights its ongoing SYMON-II validation study, intended to further evaluate IL-6 as a prognostic biomarker linked to mortality and other clinically meaningful outcomes in critically ill patients.
Bluejay Diagnostics, Inc. faces new shareholder pressure as Northstrive Fund II LP and Braeden Lichti file a Schedule 13D on the company’s common stock. As of March 10, 2026, Lichti beneficially owns 35,500 shares, or 3.65% of the 972,000 shares outstanding, while Northstrive Fund II LP owns 11,000 shares, or 1.13%.
The investors sent a March 11, 2026 letter to Bluejay’s board recommending review of a potential biotechnology acquisition they identified to strengthen the clinical pipeline and, in their view, accelerate shareholder value creation. They signal possible future changes in their position, including buying more or selling shares, and may consider actions that could influence control of the company.
Bluejay Diagnostics, Inc. received an updated ownership filing from investor Braeden Lichti and Northstrive Fund II LP, who are now reporting as active investors. As of March 10, 2026, Lichti beneficially owned 35,500 shares of common stock, or 3.65% of the company, while Northstrive Fund II LP owned 11,000 shares, or 1.13%. Both stakes are calculated against 972,000 shares outstanding, as reported in a recent company press release. The investors sent a letter to Bluejay’s board on March 11, 2026, recommending that the board review a potential biotechnology acquisition opportunity that they believe could strengthen the clinical pipeline and accelerate shareholder value. Because this communication may be intended to influence control or strategy, they switched from a passive Schedule 13G to this Schedule 13D and state they may buy more, sell, or pursue other strategic actions over time.
Northstrive Fund II LP and Braeden Lichti have filed a Schedule 13D on Bluejay Diagnostics, Inc. They report beneficial ownership of 11,000 and 35,500 shares of common stock, respectively, representing 1.13% and 3.65% of the 972,000 shares outstanding as referenced in a recent company press release.
The filing discloses a letter sent on March 11, 2026 to Bluejay’s board recommending that it review a potential biotechnology acquisition opportunity identified by Northstrive to strengthen the clinical pipeline. The investors indicate they may increase or reduce their stake over time and may consider actions that could influence control of the company.
Bluejay Diagnostics, Inc. is a development‑stage medical diagnostics company focused on its Symphony platform and an IL‑6 test for assessing 28‑day mortality risk in sepsis and septic shock patients in ICUs. Symphony is not yet FDA cleared, and the company has no revenue‑generating operations.
Bluejay has completed pre‑clinical development of the Symphony analyzer and is working with contract manufacturer Sanyoseiko in Japan to redevelop and validate disposable cartridges for FDA submission and future commercialization. A pivotal SYMON‑II clinical trial is underway, with about 583 of a targeted 750 patients enrolled and samples biobanked for later testing.
As of December 31, 2025, the company reported an accumulated deficit of about $41.5 million and an operating loss of roughly $6.8 million for 2025. Management expects to raise at least $20 million by the end of fiscal 2027 to execute its plan to analyze SYMON‑II samples in 2026, submit a 510(k) application in 2027 and pursue FDA clearance, and warns it may run out of cash in the third quarter of 2026 without new capital.
The filing highlights substantial risks, including going‑concern uncertainty, dependence on Toray’s cartridge IP and Sanyoseiko’s manufacturing, multiple highly dilutive financings and reverse stock splits aggregating 1‑for‑32,000 since July 2023, extensive outstanding warrants, and the possibility of Nasdaq delisting based on minimum bid price, market value and a proposed $5 million market value of listed securities standard.
Bluejay Diagnostics, Inc. filed a current report after issuing a press release that outlines its 2026 strategic outlook and recent progress. The company continues advancing its Symphony platform and SYMON II clinical study for an Interleukin-6 test to support sepsis risk assessment, with enrollment and site activity proceeding as planned for regulatory purposes.
Bluejay reports ongoing manufacturing scale-up, supply-chain work, and process validation to prepare for potential commercialization. During February 2026, previously issued prefunded warrants were fully exercised and converted into common shares, leaving approximately 972,000 common shares outstanding plus cash-exercisable warrants with strike prices above current trading levels.
The company expects to report $5.2 million in cash and cash equivalents and $6.0 million in stockholders’ equity as of December 31, 2025, after a $3.8 million warrant-inducement financing in April 2025 and a $4.5 million PIPE in October 2025. Net loss for 2025 was about $6.8 million. Management states that 2026 priorities center on clinical validation, manufacturing readiness, and positioning the Symphony platform for future regulatory submission and commercialization.